Boukobza G
Rev Fr Gynecol Obstet. 1986 Sep 1;81(8):413-7.
An open ended multicentric study has enabled to evaluate the efficacy and the tolerance of veralipride on sudden flushes and associated disorders of menopause. It included 166 women (125 in natural menopause) between the ages of 32 and 68 (mean age: 52). Veralipride was administered at a dose of 100 mg/day (1 capsule) for three sequences of 20 days separated by 10 days without treatment. The results were observed on 138 cases (28 withdrawals) at DO, D3M (after 3 months of treatment), D6M (three months after interruption of the treatment). The results were considered as excellent or good in 89.9 per cent of the cases at D3M. Three months later, the results were still excellent or good in 64.5 per cent of the cases. The self evaluation by the patients gave similar results: 91.1 per cent of favorable opinions at D3M and 80.7 per cent at D6M. The systolic and diastolic blood pressure did not vary during the observation period. These results confirm those obtained in previous studies.
一项开放性多中心研究得以评估维拉必利对潮热及相关更年期症状的疗效和耐受性。该研究纳入了166名年龄在32岁至68岁(平均年龄:52岁)之间的女性(125名自然绝经女性)。维拉必利以100毫克/天(1粒胶囊)的剂量给药,共三个疗程,每个疗程20天,疗程之间间隔10天不给药。在治疗开始日(DO)、治疗3个月后(D3M)、治疗中断3个月后(D6M)对138例患者(28例退出)进行了观察。在D3M时,89.9%的病例结果被认为优秀或良好。三个月后,64.5%的病例结果仍为优秀或良好。患者的自我评价给出了类似结果:D3M时91.1%的评价为正面,D6M时为80.7%。观察期间收缩压和舒张压未发生变化。这些结果证实了先前研究中获得的结果。